Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma 
Welcome,         Profile    Billing    Logout  

6 Trials

   Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma
MI22-00013, NCT06273020: Effect of Cerebrolysin on the Blood Brain Barrier in Patients With Diabetes and Ischemic Stroke

Recruiting
4
60
RoW
Cerebrolysin, Brain-MRI with contrast after 10-14 days of cerebrolysin
Hospital Universitario Dr. Jose E. Gonzalez, Ever Neuro Pharma GmbH
Ischemic Stroke, Acute, Diabetes Mellitus, Type 2, Blood Brain Barrier
11/24
12/24
NCT04427241: Efficacy and Safety of Cerebrolysin on Prolonged Disorders of Consciousness

Not yet recruiting
4
12
RoW
Cerebrolysin, Control
Konkuk University Medical Center, Ever Neuro Pharma GmbH
Disorder of Consciousness, Hemorrhagic Stroke
07/25
12/25
NCT04904341: Efficacy of Cerebrolysin Treatment as an add-on Therapy to Mechanical Thrombectomy in Acute Ischemic Stroke.

Recruiting
3
50
Europe
Cerebrolysin
Military Institute of Medicine, Poland, Brainomix Limited
Stroke, Ischemic, Stroke, Acute, Stroke Sequelae
12/23
12/24
2019-001799-12: A clinical study on stimulating the brain to improve the function of a stroke-damaged arm Eine klinische Studie über die Stimulierung des Gehirns zur Funktionsverbesserung des durch einen Schlaganfall geschädigten Armes

Not yet recruiting
2
90
Europe
Cerebrolysin, Concentrate for solution for infusion, Cerebrolysin® - parenteral solution
EVER Neuro Pharma GmbH, EVER Neuro Pharma GmbH, VASCage GmbH
Subacute and chronic stroke, Medical condition several months after stroke, Diseases [C] - Nervous System Diseases [C10]
 
 
CERICA, NCT05755997: CERebrolysin In CADASIL

Recruiting
2
30
RoW
Cerebrolysin, Renacenz, 0.9 % NaCl, Sodium Chloride
Ever Neuro Pharma GmbH, idv Datenanalyse & Versuchsplanung, XClinical GmbH
Cadasil
03/26
12/26
C-REGS2, NCT03480698: Cerebrolysin REGistry Study in Stroke - a High-quality Observational Study of Comparative Effectiveness

Active, not recruiting
N/A
1851
Europe
Cerebrolysin
Ever Neuro Pharma GmbH, IDV Data analysis and study planning Dr. Rahlfs
Acute Ischemic Stroke
04/24
10/24

Download Options